FDA approves first drug for chronic lung condition bronchiectasis

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has approved Insmed’s daily pill brensocatib, which will be sold under the brand name Brinsupri. The drug is designed to treat non-cystic fibrosis bronchiectasis (NCFB), a chronic condition that damages the lungs and makes it harder to clear mucus, the company said in a statement.